These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 27023693

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [Abstract] [Full Text] [Related]

  • 4. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [Abstract] [Full Text] [Related]

  • 5. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 6. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 7. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y.
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [Abstract] [Full Text] [Related]

  • 8. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 9. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
    Lee S, Xie L, Wang Y, Vaidya N, Baser O.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
    [Abstract] [Full Text] [Related]

  • 11. Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database.
    Feldman SR, Tian H, Wang X, Germino R.
    J Manag Care Spec Pharm; 2019 Apr; 25(4):479-488. PubMed ID: 30556761
    [Abstract] [Full Text] [Related]

  • 12. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [Abstract] [Full Text] [Related]

  • 13. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ, Pelletier C, Ung B, Tian M.
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [Abstract] [Full Text] [Related]

  • 14. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R.
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [Abstract] [Full Text] [Related]

  • 15. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A, Burge R, Malatestinic W, Brnabic A, Guo J, Janardhanan M, Zhu B.
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
    Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab P.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P.
    J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.